The soaring valuation of SpaceX, approaching £160 billion, casts a long shadow over the space sector, prompting speculation about the fortunes of Rocket Lab and AST SpaceMobile. However, rather than...
Explore unparalleled investment opportunities amidst high market valuations. Discover companies like DLocal and Oscar Health with unique growth catalysts distinct from macro trends. Dive into thematic diversification with AMD's AI...
Baidu's dramatic underperformance compared to the S&P 500 highlights a challenging year, with its decline of 24% overshadowed by the index's 14% gain. A cocktail of sluggish Chinese economic factors...
Alphabet's autonomous vehicle division, Waymo, is at a pivotal juncture, navigating the intriguing balance between technological promise and financial reality. With confirmed data indicating 50,000 weekly paid trips, ambitious projections...
Discover why the European defence sector, spearheaded by Rheinmetall, is experiencing a structural re-rating fuelled by a fundamental security shift. With a remarkable €40 billion order backlog, Rheinmetall’s growth trajectory...
Waymo has taken a bold step by introducing teen accounts for its autonomous vehicles in Phoenix, marking a strategic shift towards embedding driverless cars in suburban life. This move allows...
Zeta Global has marked a pivotal moment by achieving its first-ever GAAP profitable quarter in Q1 2024, shifting from its previous growth-at-all-costs mentality. Post-earnings, the stock spiked by over 50%...
Oscar Health ($OSCR) is caught in a gripping tug-of-war between technical resistance and a fundamental breakthrough. After being rejected at the 0.618 Fibonacci retracement level, a classic bearish signal, the...
Political rhetoric against solar energy may create market volatility, but the true risk lies in potential policy shifts, particularly changes to the Inflation Reduction Act that supports many US solar...
The recent rallies of CRISPR Therapeutics and Moderna are captivating yet divergent stories in biotech's evolving landscape. CRISPR's shift to profitability, thanks to its gene-editing therapy Casgevy, contrasts sharply with...
